Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease
In late 2012, French microbiologist Emmanuelle Charpentier approached a handful of American scientists about starting a company, a Crispr company. They included UC Berkeley\u2019s Jennifer Doudna, George Church at Harvard University, and his former postdoc Feng Zhang of the Broad Institute\u2014the brightest stars in the then-tiny field of Crispr research. Back then barely 100 papers had been published on the little-known guided DNA-cutting system. It certainly hadn\u2019t attracted any money.